• Explore /
  • Poster
  • / Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.

Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.

Abstract Poster

Authors

Elgene Lim

Elgene Lim

Olivia Newton John Cancer & Wellness Centre, Heidelberg, Australia

Elgene Lim , Adam Brufsky , Hope S. Rugo , Charles L. Vogel , Joyce O'Shaughnessy , Robert H. Getzenberg , K. Gary Barnette , Domingo Rodriguez , Gary Bird , Mitchell S. Steiner , Hannah M. Linden

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT05065411

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS1121)

DOI

10.1200/JCO.2022.40.16_suppl.TPS1121

Abstract #

TPS1121

Poster Bd #

491a

Abstract Disclosures

Similar Posters

First Author: Kelvin K H Bao

First Author: Sara A. Hurvitz

First Author: Rachel M. Layman

First Author: Tomás Pascual